Clinical

Articles

Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial. 

Withdrawal Study Details Effects of Levoketoconazole in Cushing's Syndrome

An analysis of nationwide data from Sweden provides an overview of the increased risk of death associated with Cushing's disease was present even after biochemical remission. 

Increased Risk of Death in Cushing's Disease Persists After Remission

Patrick Campbell is the assistant managing editor of Endocrinology Network, as well as its sister publication Practical Cardiology. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record.  Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.

Mild Autonomous Cortisol Secretion Linked to Increased Hypertension, Requiring Insulin Therapy

Announced on December 30, the approval of levoketoconazole (Recorlev), a cortisol synthesis inhibitor, is for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Levoketoconazole (Recorlev) Receives FDA Approval for Endogenous Cushing's Syndrome

A retrospective analysis of data from more than 170 patients with Cushing syndrome and hyperglycemia provides insight into the effects of curative treatment on hyperglycemia among these patients.

Study Details Impact of Curative Treatment on Hyperglycemia in Cushing Syndrome

Data from LINC3 and LINC4 provide insight into the impact of dosing titration schedules on risk of hypocortisolism-related adverse events associated with osilodrostat use in patients with Cushing's disease.

More Gradual Dose Titration Could Reduce Hypocortisolism Risk with Osilodrostat in Cushing's Disease

Podcasts

Georgiana Dobri, MD, a neuroendocrinologist from Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.

 Osilodrostat and Treatment of Cushing's Disease

Study of levoketoconazole for Cushing’s syndrome shows significant improvements in acne, hirsutism in women, and peripheral edema.

Phase Three Study Demonstrates Promising New Treatment for Cushing’s Syndrome

® Cushing Disease clinical resource center is a hub for the latest in the management and diagnosis of Cushing’s syndrome. Often referred to as hypercortisolism, this page will host content including articles, videos, podcasts, and clinician-authored columns.